Daptomycin
Daptomycin is an intravenous (IV) antibiotic used to treat complicated skin infections and Staphylococcus aureus bloodstream infections, with product-specific age limits.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 43 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Daptomycin is an IV antibiotic that latches onto the outer membrane of bacteria and disrupts its electrical charge, used for complicated skin infections and Staphylococcus aureus bloodstream infections, including MRSA (resistant staph), where it is a common alternative to vancomycin; it has been around since about 2003 and is available as a generic. Most people tolerate it well, and the side effects they tend to notice are diarrhea, headache or a rash. Watch most for muscle damage, reporting unexplained muscle pain or weakness, numbness or tingling, or fever with new cough or breathlessness, a rare lung reaction (it does not treat pneumonia).
Clinical pearls
- Expect weekly CPK (a muscle enzyme) blood tests, more often with kidney problems, and a statin may be paused during treatment.
- Daptomycin can falsely raise PT/INR clotting results, so tell lab staff and anyone checking your INR that you are on it.
- Report diarrhea even weeks or months after the last dose, since it can be C. difficile, a serious gut infection.
- Dapzura RT contains sorbitol, so it is not for anyone with known or suspected hereditary fructose intolerance.
Patient Information Guide A plain-language walkthrough of Daptomycin, written from its FDA label.
What Daptomycin Is Used For
▾
Daptomycin treats certain serious bacterial infections.
- Complicated skin and skin structure infections in adults (all products).
- Complicated skin infections in children 1 to 17 years (Daptomycin in Sodium Chloride Injection, Dapzura Rt, and daptomycin for injection labeled for children).
- S. aureus bloodstream infections in adults, including right-sided infective endocarditis (all products).
- S. aureus bloodstream infections in children 1 to 17 years (the products above labeled for children).
- Not for pneumonia or left-sided infective endocarditis due to S. aureus.
How Daptomycin Works
▾
Daptomycin binds to bacterial cell membranes and quickly disrupts their electrical charge. This blocks DNA, RNA and protein production. The bacteria then die.
Daptomycin Dosage
▾
Daptomycin is given by IV, usually once every 24 hours, by a healthcare professional. Dapzura Rt is given in 0.9% sodium chloride as a 2-minute injection or 30-minute infusion in adults. Treatment lasts roughly 1 to 2 weeks for skin infections and 2 to 6 weeks for bloodstream infections (per the Dapzura Rt label). Your prescriber sets the exact plan.
Dosing details from the FDA-approved label
From the Daptomycin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- cSSSI (complicated skin and skin structure infections), adult patients with creatinine clearance ≥30 mL/min
- 4 mg/kg once every 24 hours for 7 to 14 days, administered intravenously in 0.9% sodium chloride, either by injection over a 2-minute period or by infusion over a 30-minute period
- Regimen listed for CLCR ≥30 mL/min
- S. aureus Bacteremia, adult patients with creatinine clearance ≥30 mL/min
- 6 mg/kg once every 24 hours for 2 to 6 weeks, administered intravenously in 0.9% sodium chloride, either by injection over a 2-minute period or by infusion over a 30-minute period
- Regimen listed for CLCR ≥30 mL/min
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Adult Patients • Administer to adult patients intravenously either by injection over a 2-minute period or by infusion over a 30-minute period. ( 2.1 , 2.7 ) • Recommended dosage regimen for adult patients ( 2.2 , 2.4 , 2.6 ): Creatinine Clearance (CL CR ) Dosage Regimen cSSSI For 7 to 14 days S. aureus Bacteremia For 2 to 6 weeks ≥ 30 mL/min 4 mg/kg once every 24 hours 6 mg/kg once every 24 hours < 30 mL/min, including hemodialysis and CAPD 4 mg/kg once every 48 hours Administered following hemodialysis on hemodialysis days. 6 mg/kg once every 48 hours Pediatric Patients • Unlike in adults, do NOT administer by injection over a two (2) minute period to pediatric patients. ( 2.1 , 2.7 ) • Administer to pediatric patients intravenously by infusion over a 30- or 60-minute period, based on age. ( 2.1 , 2.7 ) • Recommended dosage regimen for pediatric patients (1 to 17 years of age) with cSSSI, based on age ( 2.3 ): Age group Dosage Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established. Duration of therapy 12 to 17 years 5 mg/kg once every 24 hours infused over 30 minutes Up to 14 days 7 to 11 years 7 mg/kg once every 24 hours infused over 30 minutes 2 to 6 years 9 mg/kg once every 24 hours infused over 60 minutes 1 to less than 2 years 10 mg/kg once every 24 hours infused over 60 minutes • Recommended dosage regimen for pediatric patients (1 to 17 years of age) with S. aureus bacteremia, based on age ( 2.5 ): Age group Dosage Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established. Duration of therapy 12 to 17 years 7 mg/kg once every 24 hours infused over 30 minutes Up to 42 days 7 to 11 years 9 mg/kg once every 24 hours infused over 30 minutes 1 to 6 years 12 mg/kg once every 24 hours infused over 60 minutes • There are two formulations of daptomycin that have differences concerning storage and reconstitution. Carefully follow the reconstitution and storage procedures in labeling. ( 2.7 ) • Do not use in conjunction with ReadyMED ® elastomeric infusion pumps in adult and pediatric patients.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Daptomycin Side Effects
▾
Common side effects in studies included:
Common side effects
- Diarrhea
- Headache
- Dizziness
- Rash
- Elevated CPK (a muscle enzyme seen on blood tests)
- Abnormal liver function tests
- Vomiting and abdominal pain (more noted in children)
- Itching
- Urinary tract infections, low blood pressure, shortness of breath (adults with skin infections)
When to get medical help
- Call for help right away if you have signs of a serious allergic reaction, such as trouble breathing or swelling.
- Tell your doctor about unexplained muscle pain or weakness, especially in the arms or legs.
- Report fever, shortness of breath or new cough, which can signal eosinophilic pneumonia (a lung reaction).
- Report skin rash with fever and signs of organ problems, which can signal DRESS (a severe drug reaction).
- Report new or worsening kidney problems.
- Report numbness, tingling or other nerve symptoms.
- Tell your doctor about diarrhea, even weeks or months after treatment ends.
- Report an infection that persists or returns during treatment.
Seek help for allergic reactions, muscle pain or weakness, breathing problems, nerve symptoms, kidney changes or ongoing diarrhea.
Daptomycin Warnings and Precautions
▾
- Serious allergic reactions can occur and can be life-threatening.
- Muscle damage (myopathy, rhabdomyolysis): CPK is monitored weekly.
- Eosinophilic pneumonia, usually 2 to 4 weeks after starting.
- DRESS and tubulointerstitial nephritis (kidney inflammation).
- Peripheral neuropathy (nerve damage).
- C. difficile–associated diarrhea, which can appear more than 2 months after treatment.
- Avoid in children under 12 months because of nerve and muscle effects seen in young dogs.
Daptomycin Interactions
▾
A few things matter with daptomycin:
- Statins: both can affect muscles, so your doctor may pause the statin.
- Clotting tests: daptomycin can falsely raise PT/INR with some lab reagents.
Interactions listed in the FDA-approved label
From the Daptomycin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- HMG-CoA reductase inhibitors: In healthy adult subjects, simvastatin trough concentrations were unaffected and no skeletal myopathy was reported, but HMG-CoA reductase inhibitors may cause myopathy (muscle pain or weakness with elevated CPK), and some patients in the adult Phase 3 S. aureus bacteremia/endocarditis trial who received prior or concomitant treatment developed elevated CPK. Experience with coadministration is limited; consider temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving daptomycin.
- Laboratory tests: prothrombin time (PT)/INR with recombinant thromboplastin reagents: Clinically relevant plasma concentrations of daptomycin can cause a significant concentration-dependent false prolongation of PT and elevation of INR when certain recombinant thromboplastin reagents are used. Draw specimens near trough daptomycin concentration; if PT/INR is abnormally high, repeat the assessment with the specimen drawn just prior to the next dose, consider an alternative method if it remains substantially elevated, and evaluate for other causes.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 HMG-CoA Reductase Inhibitors In healthy adult subjects, concomitant administration of daptomycin for injection and simvastatin had no effect on plasma trough concentrations of simvastatin, and there were no reports of skeletal myopathy [see Clinical Pharmacology (12.3) ]. However, inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of creatine phosphokinase (CPK). In the adult Phase 3 S. aureus bacteremia/endocarditis trial, some patients who received prior or concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK [see Adverse Reactions (6.1) ]. Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. 7.2 Drug-Laboratory Test Interactions Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1. Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Daptomycin
▾
- Known allergy to daptomycin: do not use.
- Hereditary fructose intolerance: Dapzura Rt contains sorbitol and is contraindicated.
- Kidney impairment: closer monitoring is needed, and effectiveness may be lower with moderate impairment.
- Children under 1 year: not recommended.
- Pregnancy: limited human data; animal studies showed no developmental harm.
- Breastfeeding: small amounts pass into milk.
- Older adults: clinical success was lower in those 65 and older.
Daptomycin Overdose
▾
In an overdose, supportive care is advised, with kidney filtration maintained. Hemodialysis removes about 15% of a dose over 4 hours, and peritoneal dialysis about 11% over 48 hours.
What Daptomycin Does in the Body
▾
Daptomycin's antibacterial activity in animal models appears to track the AUC/MIC ratio, a measure of drug exposure relative to how easily the bacteria are stopped. The measure best linked to cure in people has not been determined.
How Your Body Processes Daptomycin
▾
Daptomycin is about 90 to 93% bound to blood proteins, mainly albumin. With daily dosing, steady levels are reached by the third dose. Its half-life is roughly 8 hours in healthy adults.
How to Store Daptomycin
▾
Store original packages at refrigerated temperatures, 2° to 8°C (36° to 46°F); avoid excessive heat. for the reconstituted and diluted solutions are described in another section of the prescribing information .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Daptomycin: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Daptomycin — the kind of thing our pharmacy team would talk through with you at the counter.
What is daptomycin for?
▾
How will I get it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
I take a statin. Is that a problem?
▾
Can I use it while pregnant or breastfeeding?
▾
Is Daptomycin available over the counter?
▾
When was Daptomycin first available?
▾
Who makes Daptomycin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Daptomycin on HelloPharmacist
Daptomycin Forms and Strengths (How It Comes)
Daptomycin is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Daptomycin inactive ingredients by manufacturer.
Injection
How this form is used
- Daptomycin in Sodium Chloride Injection is used for cSSSI in adults and children 1 to 17 years, and S. aureus bloodstream infections in adults and children 1 to 17 years.
- Dapzura Rt is used for cSSSI and S. aureus bloodstream infections in adults and children 1 to 17 years.
- Daptomycin for Injection (adult-labeled product) is used for cSSSI and S. aureus bloodstream infections in adults.
- Dapzura Rt is given intravenously in 0.9% sodium chloride, as an injection over 2 minutes or an infusion over 30 minutes in adults.
- Daptomycin in Sodium Chloride Injection is not recommended in children when the needed dose is not 350, 500, 700 or 1,000 mg, because fractional doses are not recommended.
Show 3 more strengths Show fewer strengths
Daptomycin on the U.S. Market: Products, Makers and Brands
How Daptomycin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
25 companies list 47 Daptomycin product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2003. Brand names on the directory include Dapzura, Cubicin, Daptomycin in Sodium Chloride and 1 more; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (8) · Unfinished injection, powder, lyophilized, for solution (2) · Unfinished liquid (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Daptomycin Is Used (Medicaid Data)
A general measure of how commonly Daptomycin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Daptomycin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Daptomycin prescribed? Of the 1,603 medications we measure, Daptomycin ranks #503 by Medicaid prescriptions — more than 69% of them.
Utilization by Daptomycin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
daptomycin 500 MG Injection Most dispensed
Summed across the 27 of 44 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 403920
daptomycin 350 MG Injection
Summed across the 16 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1996246
50 ML daptomycin 10 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2632132
100 ML daptomycin 7 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2632133
100 ML daptomycin 10 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2632127
50 ML daptomycin 7 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2632130
Other Daptomycin products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 2 of 37 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Daptomycin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 49 of 109 listed Daptomycin NDCs with Medicaid activity.
Compare Daptomycin Products
A representative set of FDA-listed product records for Daptomycin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 350 mg/7 mL | Intravenous | Accord Healthcare, Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Accord Healthcare Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Apotex Corp. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Aspiro Pharma Limited | ANDA | View NDC → |
| 350 mg/50 mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 500 mg/50 mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 700 mg/100 mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 1000 mg/100 mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 350 mg/7 mL | Intravenous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | BE Pharmaceuticals Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Biocon Pharma Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | Civica, Inc. | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Civica, Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Civica, Inc. | NDA | View NDC → |
| 350 mg/7 mL | Intravenous | Dr. Reddy's Laboratories Inc., | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Dr.Reddy's Laboratories Inc., | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Hainan Poly Pharm., Co., Ltd. | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | Hikma Pharmaceuticals USA Inc. × 2 listings | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Hikma Pharmaceuticals USA Inc. × 2 listings | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Hikma Pharmaceuticals USA Inc. | NDA | View NDC → |
| 350 mg/7 mL | Intravenous | Hospira, Inc. | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Hospira, Inc. | NDA | View NDC → |
| 500 mg | Intravenous | MAIA Pharmaceuticals, Inc. | NDA | View NDC → |
| 350 mg/7 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Mylan Institutional LLC × 2 listings | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | NorthStar RxLLC | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | NorthStar RxLLC | ANDA | View NDC → |
| 500 mg | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 50 mg/mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | Sagent Pharmaceuticals | NDA | View NDC → |
| 500 mg/20 mL | Intravenous | Sintetica US LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| 350 mg/7 mL | Intravenous | Xellia Pharmaceuticals USA LLC × 2 listings | NDA | View NDC → |
| 500 mg/10 mL | Intravenous | Xellia Pharmaceuticals USA LLC | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Xellia Pharmaceuticals USA LLC | NDA | View NDC → |
Showing 47 of 47 products — FDA National Drug Code Directory. See every product, package size and price: browse all 47 Daptomycin NDCs →
Daptomycin Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Daptomycin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Daptomycin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Daptomycin FDA Approval History
How Daptomycin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Daptomycin Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Daptomycin recall since July 2021, covering 2 product listings. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Daptomycin for Injection 500 mg per vial, Single-dose vial, Rx only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. NDC 16729-435-05 UPC 3 16729 43505 5. Lots: Batches: R2101282, Exp. Date 9/30/2023; R2101600,Exp. Date 11/30/2024; R2200002, R2200028, R2200116, R2200142, R2200152, Exp. Date 12/31/2024; R2200165, R2200190, Exp. Date 1/31/2025; R2201042, Exp. Date 7/31/2025; FDA record D-0382-2023 →
- Daptomycin for Injection 350 mg/vial, Rx only, Packaged as: a) Single-dose vial NDC 16729-434-05 UPC 3 16729 43405 8; b) 10 Single-dose vials NDC 16729-434-45 UPC 3 16729 43445 4 Manufactured by: Int… Lots: Batches: a) R2101274, Exp. Date 9/30/2023; R2200161, Exp. Date 1/31/2025; R2200506, Exp. Date 1/31/2025; R2200697, Exp. Date 4/30/2025; R2201107, Exp. Date 7/31/2025; b) R2101471, Exp. Date 9/30/2023; R2200588, Exp. Date 4/30/2025; R220133… FDA record D-0381-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 22299 1 dose form · 6 strengths
-
Dose form (SCDF) Injection RxCUI 1731096In current FDA listingsClinical drug / strength (SCD) 50 ML daptomycin 10 MG/MLRxCUI 263213250 ML daptomycin 7 MG/MLRxCUI 2632130100 ML daptomycin 10 MG/MLRxCUI 2632127100 ML daptomycin 7 MG/MLRxCUI 2632133350 MGRxCUI 1996246500 MGRxCUI 403920
Look up RxCUI 22299 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Daptomycin Supply and Shortage Status
Whether Daptomycin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Daptomycin Costs Pharmacies (NADAC Benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Oct 7, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection, Powder, Lyophilized, For Solution · Intravenous | 500 mg/10 mL | $23.80 each | NDC details & price history |
| Injection, Powder, Lyophilized, For Solution · Intravenous | 350 mg/7 mL | $13.42 each | NDC details & price history |
| Injection, Powder, Lyophilized, For Solution · Intravenous | 50 mg/mL | $23.80 each | NDC details & price history |
| Injection, Powder, Lyophilized, For Solution · Intravenous | 500 mg | $20.77 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Daptomycin Brand Names
Daptomycin is sold under 4 brand names in the FDA directory — Dapzura, Cubicin, Daptomycin in Sodium Chloride, Dapzura Rt. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who Makes Daptomycin: Manufacturers and Labelers
25 companies list Daptomycin products with the FDA. By number of product records, the largest are Baxter Healthcare Corporation, Hikma Pharmaceuticals USA Inc., Xellia Pharmaceuticals USA LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 1 more on the FDA NDC directory.
Daptomycin Drug Class (RxNorm)
Daptomycin belongs to the Lipopeptide Antibacterial class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for This Daptomycin Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Baxter Healthcare Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →